5 years ago

Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: a systematic review, network meta-analysis and cost analysis

Skin and soft tissue infections (SSTIs) carry significant economic burden, as well as morbidity and mortality, especially when caused by methicillin-resistant Staphylococcus aureus (MRSA). Several new MRSA-active antibiotics have been developed, including semisynthetic glycopeptides (telavancin, dalbavancin and oritavancin). Of these, dalbavancin and oritavancin offer extended dosing intervals. Methods We performed a systematic review, network meta-analysis and cost analysis to compare the newer glycopeptides to standard care and each other for the treatment of complicated SSTIs (cSSTI). A search for randomized controlled trials (RCTs) was conducted in MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials. We also developed a model to evaluate the costs associated with dalbavancin and oritavancin from the third-party payer perspective. Results Seven RCTs met inclusion criteria. Network meta-analyses suggested that the clinical response to telavancin, dalbavancin and oritavancin was similar to standard care (odds ratio [OR] 1.09, 95% confidence interval [CI] 0.90-1.33; OR 0.78, CI 0.52-1.18; and OR 1.06, CI 0.85-1.33, respectively). Head-to-head comparisons showed no difference in clinical response between oritavancin and dalbavancin (OR 1.36; CI 0.85-2.18), oritavancin and telavancin (OR 0.98; CI 0.72-1.31) or dalbavancin and telavancin (OR 0.72; CI 0.45-1.13). Telavancin had a higher incidence of overall adverse events compared to standard care (OR 1.33; CI 1.10-1.61). Compared to telavancin, there were fewer overall adverse events with dalbavancin (OR 0.58; CI 0.45-0.76) and oritavancin (OR 0.71; CI 0.55-0.92). Studies were of high quality overall. Our cost analyses demonstrated that dalbavancin and oritavancin were less costly compared to standard care under baseline assumptions and many scenarios evaluated. The use of dalbavancin could save third-party payers $1,442 to $4,803 per cSSTI, while the use of oritavancin could save $3,571 to $6,932 per cSSTI. Conclusions Dalbavancin and oritavancin demonstrate efficacy and safety comparable to standard care in well-designed RCTs and result in cost savings when standard care is treatment that covers MRSA.

Publisher URL: www.sciencedirect.com/science

DOI: S1198743X17304913

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.